Newsletter
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Publications
09.11.2022
ISPOR 2022 Plenary Session 3 - Integrating Data

Our experts provide a detailed summary of Plenary Session 2 at ISPOR 2022 on innovative methods for ...

Read more
Publications
08.11.2022
ISPOR 2022 Plenary Session 2 - Real-World Research

Our experts provide a detailed summary of Plenary Session 2 at ISPOR 2022 on real-world patient-cent...

Read more
Publications
07.11.2022
ISPOR 2022 Plenary Session 1 - HTA and Regulation

Our experts provide a detailed summary of Plenary Session 1 at ISPOR 2022 on the Convergence of HTA ...

Read more
Publications
12.10.2022
ISPOR 2022: Do manufacturers still see value in su...

Our research is aimed at identifying trends in terminated appraisals in relation to therapeutic area...

Read more
Publications
12.10.2022
ISPOR 2022: Could Netflix Based Subscription Model...

We analyse subscription-based agreements for antibiotics in Europe to understand how it may address ...

Read more
Publications
12.10.2022
ISPOR 2022: Comparing and contrasting Early Access...

We've researched early access programmes across the UK and EU4 to establish the eligibility criteria...

Read more
Insider Insights
12.10.2022
France: Implications for Pharma of the proposed So...

Leem report the changes set out by the Government will heighten the difficulties already being faced...

Read more
Articles
12.10.2022
How important is HTA when launching a biosimilar i...

The short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...

Read more
Insider Insights
06.10.2022
Germany: Pros and cons of register-based randomise...

Study designs that combine explanatory and pragmatic aspects have recently been weighted up by autho...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.